Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

TAVI in LOW RISK in the REAL WORLD (TAVI IN LOW R)

18. mai 2026 oppdatert av: Centro Cardiologico Monzino
The primary objective is to assess all-cause mortality, the occurrence of stroke, or rehospitalization for cardiovascular causes in low-risk "all-comers" patients following percutaneous aortic valve replacement

Studieoversikt

Status

Fullført

Detaljert beskrivelse

Severe aortic stenosis is the most common valvular heart disease worldwide. Its prevalence increases with age and is estimated to affect approximately 2% of the population aged 70-80 and as many as 9% of adults over 80 years of age.¹ Given the progressive aging of the population and the ever-increasing life expectancy, its prevalence will continue to rise, representing not only a topic of scientific interest but also a significant public health issue. In the past, the treatment of severe aortic stenosis was strictly the domain of cardiac surgery, and the gold standard was aortic valve replacement via open-heart surgery. In 2002, however, in an effort to offer a compassionate treatment option to patients considered high-risk or even ineligible for traditional surgery, transcatheter aortic valve replacement (TAVI) was introduced. The PARTNER study was the first randomized trial to evaluate the use of a balloon-expandable valve (Sapien - Edwards). The study consisted of two cohorts: Cohort A, comprising patients at high surgical risk, demonstrated that TAVI was non-inferior to SAVR in terms of 1-year all-cause mortality.

And a second cohort, Cohort B, which enrolled patients who were not considered suitable candidates for surgical aortic valve replacement (SAVR) and demonstrated a reduction in the rate of all-cause mortality or rehospitalization with transcatheter aortic valve implantation (TAVI) compared with standard medical therapy.² The efficacy and safety of transcatheter aortic valve replacement were quickly recognized by the ESC/EACTS and ACC/AHA, which incorporated this technique into their guidelines in 2012 and 2014, respectively. TAVI was in fact recommended as a Class I recommendation for patients ineligible for cardiac surgery and as a Class IIA recommendation for high-risk patients. At the same time, the CoreValve Extreme Risk Pivotal and CoreValve US Pivotal studies demonstrated the safety and efficacy of a self-expanding valve in the treatment of aortic stenosis (CoreValve - Medtronic); and in the second study, even its superiority over traditional surgery.

Since then, several studies have been conducted to demonstrate the safety and efficacy (non-inferiority) of TAVI compared to SAVR, even in intermediate-risk patients, including PARTNER 2 (which used a second-generation Sapien XT valve) and SURTAVI (CoreValve and Evolut R). Once again, guidelines were not long in coming, and in 2017, the ESC/EACTS classified the use of TAVI in patients with increased risk (intermediate or high) as Class I. Two further studies, PARTNER 3 and Evolut Low Risk, subsequently demonstrated the non-inferiority of TAVI compared to SAVR, thereby securing approval in Europe and the United States for use in low-risk patients. These valves have distinguished themselves by achieving excellent results across various outcomes in low-risk patients. In fact, Sapien 3 demonstrated superior results in terms of 1-year mortality and stroke rates and a lower need for pacemaker implantation compared to Evolut, which, however, achieved better hemodynamic performance within its own studies. Currently, registries showing TAVI outcomes in real-world patients are few and limited; therefore, it is important to assess whether data on outcomes in low-risk all-comers outside of trial settings align with trial results.

Patients included in the retrospective part of the study will be enrolled from January 2021 through September 2024 and will account for approximately two-thirds of the patients enrolled in the CCM.

Patients included in the prospective part of the study will be enrolled from October 2024 through August 2025.

For all patients deemed eligible, data will be collected regarding the screening/baseline visit, procedural data, discharge, and 12-month follow-up

Studietype

Observasjonsmessig

Registrering (Faktiske)

650

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • BS
      • Brescia, BS, Italia, 25124
        • Fondazione Poliambulanza Istituto Ospedaliero, Unità Emodinamica

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Consecutive patients with symptomatic severe aortic valve stenosis and low surgical risk-defined as an STS-PROM score (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) of less than 4% and no major organ damage-who were treated with TAVI.

Beskrivelse

Inclusion Criteria:

  • Patients aged 18 years or older
  • Patients with severe symptomatic aortic valve stenosis undergoing TAVI.
  • Patients considered to be at low surgical risk, defined as an STS-PROM (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) score of less than 4% and no major organ damage.

Exclusion Criteria:

  • Patients who required emergency aortic valve replacement for any reason
  • Need for conversion to SAVR during the procedure
  • Patients who refused to consent to participate in the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Patients with symptomatic severe aortic valve stenosis
Consecutive patients with symptomatic severe aortic valve stenosis and low surgical risk-defined as an STS-PROM score (Society of Thoracic Surgeons Predicted Risk of Mortality for isolated SAVR) of less than 4% and no major organ damage-who were treated with TAVI.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
All-cause mortality
Tidsramme: Up to 12 months
Up to 12 months
Occurrence of stroke
Tidsramme: Up to 12 months
Up to 12 months
Rehospitalization for cardiovascular causes
Tidsramme: Up to 12 months
Up to 12 months

Sekundære resultatmål

Resultatmål
Tidsramme
Occurrence of major or minor bleeding
Tidsramme: Up to 12 months
Up to 12 months
Implantation of a permanent pacemaker
Tidsramme: Up to 12 months
Up to 12 months
Development of paroxysmal or permanent atrial fibrillation
Tidsramme: Up to 12 months
Up to 12 months
Infectious causes requiring prolonged monitoring in the hospital
Tidsramme: Up to 12 months
Up to 12 months
Presence of significant paravalvular or intravalvular regurgitation
Tidsramme: Up to 12 months
Up to 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. desember 2024

Primær fullføring (Faktiske)

24. august 2025

Studiet fullført (Faktiske)

24. august 2025

Datoer for studieregistrering

Først innsendt

15. april 2026

Først innsendt som oppfylte QC-kriteriene

18. mai 2026

Først lagt ut (Faktiske)

26. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

26. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. mai 2026

Sist bekreftet

1. april 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere